ProCE Banner Activity

Advances in CDK4/6 Inhibition in EBC: Expert Guidance and Case Challenges for the Multidisciplinary Team


Download these slides from an interdisciplinary workshop series for expert guidance on identifying eligible patients and managing toxicities related to adjuvant CDK4/6 inhibitor therapy in the setting of HR-positive/HER2-negative early breast cancer.

Released: January 23, 2024



Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.


Novartis Pharmaceuticals Corporation


ProCE Banner

Smart Patients

ProCE Banner